

Resource Summary Report

Generated by [nidm-terms](#) on Aug 10, 2026

SignalStain Boost IHC Detection Reagent (HRP, Rabbit)

RRID:AB_10544930

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 8114, RRID:AB_10544930

Antibody Information

URL: http://antibodyregistry.org/AB_10544930

Proper Citation: Cell Signaling Technology Cat# 8114, RRID:AB_10544930

Target Antigen: IgG

Host Organism: goat

Clonality: unknown

Comments: Applications: IHC-P. Consolidation on 9/2016: AB_10858433.

Antibody Name: SignalStain Boost IHC Detection Reagent (HRP, Rabbit)

Description: This unknown targets IgG

Target Organism: rabbit

Antibody ID: AB_10544930

Vendor: Cell Signaling Technology

Catalog Number: 8114

Alternative Catalog Numbers: 8114P, 8114S

Record Creation Time: 20250819T224024+0000

Record Last Update: 20250820T025627+0000

Ratings and Alerts

No rating or validation information has been found for SignalStain Boost IHC Detection Reagent (HRP, Rabbit).

No alerts have been found for SignalStain Boost IHC Detection Reagent (HRP, Rabbit).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 27 mentions in open access literature.

Listed below are recent publications. The full list is available at [nidm-terms](#) .

Lin Y, et al. (2026) Integrin CD11b/CD18 reprograms macrophage polarization by suppressing ERK/STAT3 signaling to enhance antitumor immunity in colitis-associated colorectal cancer. Journal for immunotherapy of cancer, 14(6).

Ma Z, et al. (2026) Elevated PTK6 expression is associated with tumor immune microenvironment remodeling and predicts poor prognosis in endometrial carcinoma. Frontiers in medicine, 13, 1842564.

Izzo LT, et al. (2026) KLF4 Promotes a KRT13+ Hillock-Like State in Lung Squamous Cell Carcinoma. Cancer research.

McIlvried LA, et al. (2026) CGRP signaling links tumor-associated pain to immune evasion in oral squamous cell carcinoma. Cell reports, 45(2), 116994.

Ghaemi B, et al. (2026) Precision radiolabeled B-cell maturation nanobody for targeted PET imaging and radioligand therapy of disseminated multiple myeloma. Theranostics, 16(6), 2748.

Cheng X, et al. (2026) Interleukin-34-Induced Arg1+ Macrophages Play a Key Role in Breast Cancer Brain Metastasis. Cancer research communications, 6(6), 1388.

Lee EJ, et al. (2026) JIN-A02, a Mutant-Selective Fourth-Generation EGFR Inhibitor, Overcomes C797S-Mediated Resistance and Demonstrates Intracranial Activity in NSCLC. Clinical cancer research : an official journal of the American Association for Cancer Research, 32(9), 1835.

Evans AE, et al. (2025) The XPO1 Inhibitor Eltanexor Modulates the Wnt/ β -Catenin Signaling Pathway to Reduce Colorectal Cancer Tumorigenesis. Cancer research communications, 5(7), 1140.

Albuayjan HHH, et al. (2025) Role of galectin-9 in the development of gestational diabetes mellitus. Scientific reports, 15(1), 18981.

Jaehnig EJ, et al. (2025) Proteogenomic analysis of the CALGB 40601 (Alliance) HER2+ breast cancer neoadjuvant trial reveals resistance biomarkers. Cell reports. Medicine,

6(6), 102154.

Qiu S, et al. (2025) A pathological role of O-GlcNAcylation-driven TR11B production and function in lung adenocarcinoma. *Developmental cell*.

Kovács SA, et al. (2025) Unlocking the power of immune checkpoint inhibitors: Targeting YAP1 reduces anti-PD1 resistance in skin cutaneous melanoma. *British journal of pharmacology*, 182(16), 3903.

Vykoukal J, et al. (2025) Vesicle-mediated mitochondrial clearance presents an actionable metabolic vulnerability in triple-negative breast cancer. *Cell reports. Medicine*, 6(12), 102478.

Ku AT, et al. (2025) Radiogenomic Profiling of Prostate Tumors prior to External Beam Radiotherapy Converges on a Transcriptomic Signature of TGF- β Activity Driving Tumor Recurrence. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(24), 5211.

Souto EP, et al. (2025) Lineage Tracing and Single-Cell RNA Sequencing Reveal a Common Transcriptional State in Breast Cancer Tumor-Initiating Cells Characterized by IFN/STAT1 Activity. *Cancer research*, 85(8), 1390.

Sinigaglia K, et al. (2024) An ADAR1 dsRBD3-PKR kinase domain interaction on dsRNA inhibits PKR activation. *Cell reports*, 43(8), 114618.

Lee EJ, et al. (2024) Discovery of a Novel Potent EGFR Inhibitor Against EGFR Activating Mutations and On-Target Resistance in NSCLC. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 30(8), 1582.

Abo-El Fetoh ME, et al. (2023) Cyclooxygenase-2 activates EGFR-ERK1/2 pathway via PGE2-mediated ADAM-17 signaling in testosterone-induced benign prostatic hyperplasia. *Inflammopharmacology*, 31(1), 499.

Lee JD, et al. (2023) Differences in syncytia formation by SARS-CoV-2 variants modify host chromatin accessibility and cellular senescence via TP53. *Cell reports*, 42(12), 113478.

Xu X, et al. (2023) MiR-337-3p improves metabolic-associated fatty liver disease through regulation of glycolipid metabolism. *iScience*, 26(11), 108352.